Publicacions en col·laboració amb investigadors/es de Hospital Universitari de Bellvitge (28)

2024

  1. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

    Frontiers in Neurology , Vol. 15

  2. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

    Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937

  3. Unravelling Migraine Stigma: A Comprehensive Review of Its Impact and Strategies for Change

    Journal of Clinical Medicine, Vol. 13, Núm. 17

2023

  1. The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes

    Clinical Kidney Journal, Vol. 16, Núm. 10, pp. 1656-1663

2022

  1. Multidisciplinary Consensus for the Management of Pulmonary Thromboembolism

    Archivos de Bronconeumologia

  2. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

  3. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

    Journal of Headache and Pain, Vol. 22, Núm. 1

  2. Multidisciplinary consensus for the management of pulmonary thromboembolism

    Archivos de Bronconeumologia

  3. PICO questions and DELPHI methodology for the management of venous thromboembolism associated with COVID-19

    Viruses, Vol. 13, Núm. 11

2020

  1. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: The BACS score

    European Respiratory Journal, Vol. 56, Núm. 6

  2. Risk factors for non-diabetic renal disease in diabetic patients

    Clinical Kidney Journal, Vol. 13, Núm. 3, pp. 380-388

  3. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature

    Amyloid, Vol. 27, Núm. 3, pp. 163-167

2019

  1. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

  2. Standards for global cardiovascular risk management arteriosclerosis

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 1-43

2018

  1. Cancer-associated thrombosis: Beyond clinical practice guidelines-A multidisciplinary (SEMI-SEOM-SETH) expert consensus

    TH Open, Vol. 2, Núm. 4, pp. e373-e386

  2. Factors associated with poor anticoagulation control with vitamin K antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study

    Revista Clinica Espanola, Vol. 218, Núm. 7, pp. 327-335

2017

  1. Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in internal medicine and neurology departments of Spain

    Revista de Neurologia, Vol. 65, Núm. 8, pp. 361-367

  2. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

    Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136